questionText: To ask the Secretary of State for Health and Social Care, whether the review of orphan medicines regulation required by the Rare Cancers Act 2026 will consider the full pathway from regulatory authorisation to NHS patient access, including evidence generation, health technology assessment and uptake of treatments for rare cancers.
heading: Cancer: Orphan Drugs